CoChat

Resetting microbiota by Lactobacillus reuteri inhibits T reg deficiency–induced autoimmunity via adenosine A2A receptors

Open access

The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.

Abstract

Regulatory T (T reg) cell deficiency causes lethal, CD4+ T cell–driven autoimmune diseases. Stem cell transplantation is used to treat these diseases, but this procedure is limited by the availability of a suitable donor. The intestinal microbiota drives host immune homeostasis by regulating the differentiation and expansion of T reg, Th1, and Th2 cells. It is currently unclear if T reg cell deficiency–mediated autoimmune disorders can be treated by targeting the enteric microbiota. Here, we demonstrate that Foxp3+ T reg cell deficiency results in gut microbial dysbiosis and autoimmunity over the lifespan of scurfy (SF) mouse. Remodeling microbiota with Lactobacillus reuteri prolonged survival and reduced multiorgan inflammation in SF mice. L. reuteri changed the metabolomic profile disrupted by T reg cell deficiency, and a major effect was to restore levels of the purine metabolite inosine. Feeding inosine itself prolonged life and inhibited multiorgan inflammation by reducing Th1/Th2 cells and their associated cytokines. Mechanistically, the inhibition of inosine on the differentiation of Th1 and Th2 cells in vitro depended on adenosine A2A receptors, which were also required for the efficacy of inosine and of L. reuteri in vivo. These results reveal that the microbiota–inosine–A2A receptor axis might represent a potential avenue for combatting autoimmune diseases mediated by T reg cell dysfunction.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20160961

Cites

89 of 89 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Dynamics of autoimmunity development and microbiota dysbiosis over 22 d of life in T reg cell-deficient scurfy (SF) mice. (A) Percentage of IFN-γ– or IL-4–producing-CD4+ T cells in spleen of WT and SF mice at the indicated age (two-way ANOVA; n = 6–12 per group). (B) Plasma IFN-γ and IL-4 levels at the indicated age (two-way ANOVA; n = 6–12 per group). (C) Gut microbial Shannon diversity analysis (two-way ANOVA; n = 6–12 per group). (D) Gut microbial analysis of weighted unifrac-based three-dimensional PCoA plots of WT and SF mice at the indicated age (n = 6–12 per group). (E and F) Relative abundance of predominant bacteria (>1% in any sample) at the genus level (E) and relative abundance of total bacteria at the genus level (F; two-way ANOVA; n = 6–12 per group). **, P < 0.01; ***, P < 0.001. SF versus WT. Error bars represent mean ± SEM.
Figure 1. Dynamics of autoimmunity development and microbiota dysbiosis over 22 d of life in T reg cell-deficient scurfy (SF) mice. (A) Percentage of IFN-γ– or IL-4–producing-CD4+ T cells in spleen of WT and SF mice at the indicated age (two-way ANOVA; n = 6–12 per group). (B) Plasma IFN-γ and IL-4 levels at the indicated age (two-way ANOVA; n = 6–12 per group). (C) Gut microbial Shannon diversity analysis (two-way ANOVA; n = 6–12 per group). (D) Gut microbial analysis of weighted unifrac-based three-dimensional PCoA plots of WT and SF mice at the indicated age (n = 6–12 per group). (E and F) Relative abundance of predominant bacteria (>1% in any sample) at the genus level (E) and relative abundance of total bacteria at the genus level (F; two-way ANOVA; n = 6–12 per group). **, P < 0.01; ***, P < 0.001. SF versus WT. Error bars represent mean ± SEM.CC BY-NC-SA · PubMed Central
Figure 2. L. reuteri early treatment modulates the intestinal microbiota in SF mice. (A) Gut microbial Shannon diversity analysis, comparing groups of WT, SF, and SF treated with L. reuteri (SFL; one-way ANOVA; n = 10–12 per group). (B) Weighted UniFrac-based three-dimensional PCoA analysis of gut microbiota of WT, SF, and SFL mice (n = 10–12 per group). (C) Nonparametric multiple dimensional scaling analysis of gut microbiota of WT, SF, and SFL mice (n = 10–12 per group). (D–F) Relative abundance of predominant bacteria (>1% in any sample) at the phylum level [D], and at the genus level (E), and relative abundance of total bacteria at genus level (F) in feces (one-way ANOVA; n = 10–12 per group). (G) Relative abundance of Lactobacillus at the species level in feces (one-way ANOVA; n = 10–12 per group). **, P < 0.01; ***, P < 0.001. SF versus WT. #, P < 0.05; ##, P < 0.01; and ###, P < 0.001. SFL versus SF. Error bars represent mean ± SEM.
Figure 2. L. reuteri early treatment modulates the intestinal microbiota in SF mice. (A) Gut microbial Shannon diversity analysis, comparing groups of WT, SF, and SF treated with L. reuteri (SFL; one-way ANOVA; n = 10–12 per group). (B) Weighted UniFrac-based three-dimensional PCoA analysis of gut microbiota of WT, SF, and SFL mice (n = 10–12 per group). (C) Nonparametric multiple dimensional scaling analysis of gut microbiota of WT, SF, and SFL mice (n = 10–12 per group). (D–F) Relative abundance of predominant bacteria (>1% in any sample) at the phylum level [D], and at the genus level (E), and relative abundance of total bacteria at genus level (F) in feces (one-way ANOVA; n = 10–12 per group). (G) Relative abundance of Lactobacillus at the species level in feces (one-way ANOVA; n = 10–12 per group). **, P < 0.01; ***, P < 0.001. SF versus WT. #, P < 0.05; ##, P < 0.01; and ###, P < 0.001. SFL versus SF. Error bars represent mean ± SEM.CC BY-NC-SA · PubMed Central
Figure 3. L. reuteri early treatment increases survival and suppresses autoimmunity in SF mice. (A) Scheme for L. reuteri early treatment on WT or SF mice for sample analysis and survival observation. (B) Survival curves of SF and SFL mice (Kaplan-Meier survival curves and log-rank test; n = 10–17 per group). (C) Representative H&E staining of liver and lung from WT, WTL, SF, and SFL mice. Bars, 200 µm (n = 6–12 per group). (D) Quantitation of inflammatory infiltrates in liver and lung of WT, WTL, SF, and SFL (one-way ANOVA; n = 6–12 per group). (E and F) The frequency of IFN-γ or IL-4–producing-CD4+ T cells in spleen (E) and MLNs (F) of mice (one-way ANOVA; n = 6–12 per group). (G) Plasma levels of IFN-γ and IL-4 in WT, WTL, SF, and SFL mice (one-way ANOVA; n = 6–12 per group). *, P < 0.05; ***, P < 0.001. SF versus WT. #, P < 0.05; ##, P < 0.01; ###, P < 0.001. SFL versus SF. Error bars represent mean ± SEM.
Figure 3. L. reuteri early treatment increases survival and suppresses autoimmunity in SF mice. (A) Scheme for L. reuteri early treatment on WT or SF mice for sample analysis and survival observation. (B) Survival curves of SF and SFL mice (Kaplan-Meier survival curves and log-rank test; n = 10–17 per group). (C) Representative H&E staining of liver and lung from WT, WTL, SF, and SFL mice. Bars, 200 µm (n = 6–12 per group). (D) Quantitation of inflammatory infiltrates in liver and lung of WT, WTL, SF, and SFL (one-way ANOVA; n = 6–12 per group). (E and F) The frequency of IFN-γ or IL-4–producing-CD4+ T cells in spleen (E) and MLNs (F) of mice (one-way ANOVA; n = 6–12 per group). (G) Plasma levels of IFN-γ and IL-4 in WT, WTL, SF, and SFL mice (one-way ANOVA; n = 6–12 per group). *, P < 0.05; ***, P < 0.001. SF versus WT. #, P < 0.05; ##, P < 0.01; ###, P < 0.001. SFL versus SF. Error bars represent mean ± SEM.CC BY-NC-SA · PubMed Central
Figure 4. Plasma metabolomic profiles are modulated by L. reuteri early treatment of SF mice. (A) PCA clustering from plasma metabolites of WT, SF, and SFL (n = 5–6 per group). (B) Heat map of 525 metabolites in plasma of WT, SF, and SFL mice. Each lane represents a different mouse. The scale bar indicates fold change of SF versus WT or SFL versus SF (n = 5–6 per group). (C) Numbers of plasma metabolites affected, either up-regulated (↑) or down-regulated (↓; P < 0.05), by SF versus WT or SFL versus SF mice (n = 5–6 per group). (D) Heat map showing the levels of 29 plasma metabolites that were significantly altered by L. reuteri treatment in SF mice. Colors indicate fold changes with P < 0.05 (SF vs. WT or SFL vs. SF). (E) Relative quantification of metabolites related to inosine pathway in plasma (one-way ANOVA; n = 5–6 per group). *, P < 0.05; **, P < 0.01. SF versus WT. #, P < 0.05. SFL versus SF. Error bars represent mean ± SEM.
Figure 4. Plasma metabolomic profiles are modulated by L. reuteri early treatment of SF mice. (A) PCA clustering from plasma metabolites of WT, SF, and SFL (n = 5–6 per group). (B) Heat map of 525 metabolites in plasma of WT, SF, and SFL mice. Each lane represents a different mouse. The scale bar indicates fold change of SF versus WT or SFL versus SF (n = 5–6 per group). (C) Numbers of plasma metabolites affected, either up-regulated (↑) or down-regulated (↓; P < 0.05), by SF versus WT or SFL versus SF mice (n = 5–6 per group). (D) Heat map showing the levels of 29 plasma metabolites that were significantly altered by L. reuteri treatment in SF mice. Colors indicate fold changes with P < 0.05 (SF vs. WT or SFL vs. SF). (E) Relative quantification of metabolites related to inosine pathway in plasma (one-way ANOVA; n = 5–6 per group). *, P < 0.05; **, P < 0.01. SF versus WT. #, P < 0.05. SFL versus SF. Error bars represent mean ± SEM.CC BY-NC-SA · PubMed Central
Figure 5. Inosine suppresses Th1/Th2 cell differentiation via adenosine A2A receptor in vitro. (A) mRNA expression of IFN-γ in Th1 cells with 2 mM of inosine treatment for 24 or 72 h (one-way ANOVA; n = 4 independent experiments). (B) mRNA expression of IL-4 in Th2 cells with 2 mM of inosine treatment for 24 or 72 h (one-way ANOVA; n = 4 independent experiments). (C and D) Effect of inosine on Th1 (C) or Th2 (D) cell differentiation from WT, A1−/−, A2A−/−, A2B−/−, and A3−/− mice (n = 3 independent experiments). (E and F) cAMP level in Th1 cells (E) or cAMP level in Th2 cells (F) of WT or A2A−/− mice after inosine and A2A receptor-selective agonist CGS31680 treatment (one-way ANOVA; n = 4 independent experiments). ***, P < 0.001. Error bars represent mean ± SEM.
Figure 5. Inosine suppresses Th1/Th2 cell differentiation via adenosine A2A receptor in vitro. (A) mRNA expression of IFN-γ in Th1 cells with 2 mM of inosine treatment for 24 or 72 h (one-way ANOVA; n = 4 independent experiments). (B) mRNA expression of IL-4 in Th2 cells with 2 mM of inosine treatment for 24 or 72 h (one-way ANOVA; n = 4 independent experiments). (C and D) Effect of inosine on Th1 (C) or Th2 (D) cell differentiation from WT, A1−/−, A2A−/−, A2B−/−, and A3−/− mice (n = 3 independent experiments). (E and F) cAMP level in Th1 cells (E) or cAMP level in Th2 cells (F) of WT or A2A−/− mice after inosine and A2A receptor-selective agonist CGS31680 treatment (one-way ANOVA; n = 4 independent experiments). ***, P < 0.001. Error bars represent mean ± SEM.CC BY-NC-SA · PubMed Central
Figure 6. Inosine inhibits autoimmunity in SF mice via adenosine A2A receptors. (A) Scheme of WT or SF mice treated with inosine (WTI or SFI) or inosine in combination with an A2A receptor-selective antagonist SCH58261 (WTIS or SFIS) or SF mice treated with only SCH58261 (SFS) for sample analysis and survival observation. (B) Survival curves to compare inosine-fed SF (SFI) with SF without inosine feeding (Kaplan-Meier survival curves and log-rank test; n = 8–17 per group). (C) Representative H&E staining of liver and lung from WT, WTI, WTIS, SF, SFI, SFS, and SFIS; bar, 200 µm (n = 6–12 per group). (D) Quantification of inflammatory infiltrates in liver and lung of WT, WTI, WTIS, SF, SFI, SFS, and SFIS (one-way ANOVA; n = 6–12 per group). (E) The frequency of IFN-γ or IL-4–producing CD4+ T cells in spleen of mice (one-way ANOVA; n = 6–12 per group). (F) Plasma levels of IFN-γ and IL-4 in WT, WTI, WTIS, SF, SFI, SFS, and SFIS mice (one-way ANOVA; n = 6–12 per group). ***, P < 0.001. SF versus WT. †††, P < 0.001. SFI versus SF. ‡‡‡, P < 0.001. SFIS versus SFI. Error bars represent mean ± SEM.
Figure 6. Inosine inhibits autoimmunity in SF mice via adenosine A2A receptors. (A) Scheme of WT or SF mice treated with inosine (WTI or SFI) or inosine in combination with an A2A receptor-selective antagonist SCH58261 (WTIS or SFIS) or SF mice treated with only SCH58261 (SFS) for sample analysis and survival observation. (B) Survival curves to compare inosine-fed SF (SFI) with SF without inosine feeding (Kaplan-Meier survival curves and log-rank test; n = 8–17 per group). (C) Representative H&E staining of liver and lung from WT, WTI, WTIS, SF, SFI, SFS, and SFIS; bar, 200 µm (n = 6–12 per group). (D) Quantification of inflammatory infiltrates in liver and lung of WT, WTI, WTIS, SF, SFI, SFS, and SFIS (one-way ANOVA; n = 6–12 per group). (E) The frequency of IFN-γ or IL-4–producing CD4+ T cells in spleen of mice (one-way ANOVA; n = 6–12 per group). (F) Plasma levels of IFN-γ and IL-4 in WT, WTI, WTIS, SF, SFI, SFS, and SFIS mice (one-way ANOVA; n = 6–12 per group). ***, P < 0.001. SF versus WT. †††, P < 0.001. SFI versus SF. ‡‡‡, P < 0.001. SFIS versus SFI. Error bars represent mean ± SEM.CC BY-NC-SA · PubMed Central
Figure 7. Inhibition of autoimmunity by L. reuteri is mediated by adenosine A2A receptors. (A) Scheme of SF mice treated with L. reuteri (SFL) in the combination with an A2A receptor-selective antagonist SCH58261 (SFLS) or SCH58261 alone (SFS) for sample analysis. (B) Representative H&E staining of liver and lung from SF, SFL, SFS, and SFLS mice; bar, 200 µm (n = 6–12 per group). (C) Quantification of inflammatory infiltrates in liver and lung of SF, SFL, SFS, and SFLS mice (one-way ANOVA; n = 6–12 per group). (D) The frequency of IFN-γ or IL-4–producing CD4+ T cells in spleen of mice (one-way ANOVA; n = 6–12 per group). (E) Plasma levels of IFN-γ and IL-4 in SF, SFL, SFS, and SFLS mice (one-way ANOVA; n = 6–12 per group). ##, P < 0.01; ###, P < 0.001. SFL versus SF. ‡, P < 0.05; ‡‡, P < 0.01. SFLS versus SFL. Error bars represent mean ± SEM.
Figure 7. Inhibition of autoimmunity by L. reuteri is mediated by adenosine A2A receptors. (A) Scheme of SF mice treated with L. reuteri (SFL) in the combination with an A2A receptor-selective antagonist SCH58261 (SFLS) or SCH58261 alone (SFS) for sample analysis. (B) Representative H&E staining of liver and lung from SF, SFL, SFS, and SFLS mice; bar, 200 µm (n = 6–12 per group). (C) Quantification of inflammatory infiltrates in liver and lung of SF, SFL, SFS, and SFLS mice (one-way ANOVA; n = 6–12 per group). (D) The frequency of IFN-γ or IL-4–producing CD4+ T cells in spleen of mice (one-way ANOVA; n = 6–12 per group). (E) Plasma levels of IFN-γ and IL-4 in SF, SFL, SFS, and SFLS mice (one-way ANOVA; n = 6–12 per group). ##, P < 0.01; ###, P < 0.001. SFL versus SF. ‡, P < 0.05; ‡‡, P < 0.01. SFLS versus SFL. Error bars represent mean ± SEM.CC BY-NC-SA · PubMed Central
Figure 8. Mechanisms of Lactobacillus reuteri protection against T reg cell deficiency–mediated autoimmunity. T reg cell deficiency shapes gut microbiota and induces autoimmunity resulting in multiorgan inflammation and early death (left). L. reuteri remodels gut microbiota, alters the metabolites, and protects against T reg cell deficiency–induced autoimmunity by suppressing Th1/Th2 cells via inosine–adenosine A2A interaction (right).
Figure 8. Mechanisms of Lactobacillus reuteri protection against T reg cell deficiency–mediated autoimmunity. T reg cell deficiency shapes gut microbiota and induces autoimmunity resulting in multiorgan inflammation and early death (left). L. reuteri remodels gut microbiota, alters the metabolites, and protects against T reg cell deficiency–induced autoimmunity by suppressing Th1/Th2 cells via inosine–adenosine A2A interaction (right).CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 197

Metadata

Authors
He, B., Hoang, T. K., Wang, T., Ferris, M., Taylor, C. M., Tian, X., Luo, M., Tran, D. Q., Zhou, J., Tatevian, N., Luo, F., Molina, J. G., Blackburn, M. R., Gomez, T. H., Roos, S., Rhoads, J. M., & Liu, Y.
Affiliations
  • The University of Texas Health Science Center at Houston (US)
  • Louisiana State University (US)
  • Baylor College of Medicine (US)
  • Swedish University of Agricultural Sciences (SE)
Corresponding author
  • Rhoads, J. Marc
  • Liu, Yuying
Venue
Journal of Experimental Medicine
Published
2016-12-19
Volume
214
Issue
1
Pages
107-123
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2566314801
Cited by
196
References
89
Citations by year
2026: 14 · 2025: 26 · 2024: 21 · 2023: 25 · 2022: 26 · 2021: 33 · 2020: 19 · 2019: 12 · 2018: 11 · 2017: 9
FWCI
6.47
Type
journal article
Language
en
Open access
Locations
  • The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Center for Complementary and Integrative Health (R01AT007083)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
Keywords
Lactobacillus reuteri, Foxp3, autoimmunity, gut microbiota, dysbiosis, adenosine A2A receptor, inosine, purine metabolism, Th1/Th2 cells, gut microbiota transplantation, CD4+ T cells
MeSH terms
Gastrointestinal Microbiome, Animals, Cell Differentiation, Female, Inosine, Male, Mice, Inbred C57BL, Autoimmunity, Th1 Cells, Th2 Cells, Receptor, Adenosine A2A, T-Lymphocytes, Regulatory, Mice, Limosilactobacillus reuteri, Metabolomics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.